HESG (Health Sciences Group) Debt-to-Equity: -0.09 (As of Sep. 2006)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Health Sciences Group Debt-to-Equity?

Health Sciences Group HESG -99.00% Debt-to-Equity is -0.09 as of Sep. 2006.

Health Sciences Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2006 was $0.41 Mil. Health Sciences Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2006 was $0.00 Mil. Health Sciences Group's Total Stockholders Equity for the quarter that ended in Sep. 2006 was $-4.70 Mil. Health Sciences Group's debt to equity for the quarter that ended in Sep. 2006 was -0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Health Sciences Group's Debt-to-Equity or its related term are showing as below:

HESG's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.155
* Ranked among companies with meaningful Debt-to-Equity only.

Health Sciences Group  (OTCPK:HESG) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Health Sciences Group Debt-to-Equity Related Terms

Health Sciences Group Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Health Sciences Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Health Sciences Group Debt-to-Equity Chart

Health Sciences Group Annual Data
Trend Dec00 Dec01 Dec02 Dec03 Dec04 Dec05
Debt-to-Equity
Get a 7-Day Free Trial 0.13 0.11 0.89 -0.17 -0.07

Health Sciences Group Quarterly Data
Dec01 Mar02 Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.07 -0.08 -0.08 -0.09

HESG vs VITIF, HSTC, NTRR: Debt-to-Equity Comparison

For the Biotechnology subindustry, Health Sciences Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Health Sciences Group Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Health Sciences Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Health Sciences Group's Debt-to-Equity falls into.


Health Sciences Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Health Sciences Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2005 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.335 + 0) / -4.911
=-0.07

Health Sciences Group's Debt to Equity Ratio for the quarter that ended in Sep. 2006 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.407 + 0) / -4.701
=-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.09 mean?
Health Sciences Group (HESG) has a Debt-to-Equity of -0.09 as of Sep. 2006. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Health Sciences Group and its competitors.
Is Health Sciences Group's Debt-to-Equity too high?
Health Sciences Group's current Debt-to-Equity is -0.09.
How does Health Sciences Group's Debt-to-Equity compare to VITIF and HSTC?
Health Sciences Group's Debt-to-Equity of -0.09 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Health Sciences Group and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Health Sciences Group's current Debt-to-Equity is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Sciences Group stock overvalued right now?
Health Sciences Group (HESG) has a current Debt-to-Equity of -0.09. The current Debt-to-Equity is -0.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Health Sciences Group (HESG), the current Debt-to-Equity is -0.09 as of Sep. 2006. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Health Sciences Group Business Description

Address 14331 Euclid Street, Suite 207, Garden Grove, CA, USA, 92843
Health Sciences Group Inc identifies, develops, and commercializes nutritional products. Its products are targeted towards consumers and medical professionals interested in preventative healthcare alternatives. The products are sold as nutritional supplements and functional ingredients to retail and wholesale customers in the nutrition, skin care, and food industries. The company distributes its products under the Swiss Research and Swiss Diet brand names.